Showing 3001-3010 of 3184 results for "".
- Sandoz Completes Acquisition of Fougera Pharmaceuticalshttps://practicaldermatology.com/news/20120727-sandoz_completes_acquisition_of_fougera_pharmaceuticals/2459760/Sandoz has completed its USD $1.525 billion acquisition of specialty dermatology company Fougera Pharmaceuticals. Combined with Sandoz's existing generic dermatology franchise, this acquisition positions Sandoz as the new #1 in generic dermatology
- Cone Health Pioneers Use of Fabric That Healshttps://practicaldermatology.com/news/20120726-cone_health_pioneers_use_of_fabric_that_heals/2459762/Studies find that hospital linens and gowns can be transformed into therapeutic tools when made with a smooth, antimicrobial fabric called DermaTherapy. Researchers found that patients using DermaTherapy developed 81.5 percent fewer be
- More Than 1,000 Ulthera Systems Sold Worldwidehttps://practicaldermatology.com/news/20120725-more_than_1000_ulthera_systems_sold_worldwide/2459764/Ulthera, Inc. has sold more than 1,000 Ulthera Systems globally, with more than 100,000 treatments performed using the System. Ultherapy is a non-invasive face and neck treatment to help lift and tighten. In the first half of 2012, the company rep
- Low Cancer Risk Associated with UVA Nail Lampshttps://practicaldermatology.com/news/20120720-low_cancer_risk_associated_with_uva_nail_lamps/2459767/UVA lamps used for curing gel nails pose a very low risk for development of squamous cell carcinoma (SCC) on the dorsum of hands, new research suggests. (Br J Dermatol, E-pub). In fact, researchers say that only one woman in tens of thousands using UVA lamps over a number of years will develop SCC a
- Ulthera Announces Indication for Decolletage in Asiahttps://practicaldermatology.com/news/20120709-ulthera_announces_indication_for_dcolletage_in_asia/2459776/Ulthera, Inc., a global, growth-stage medical device company, announced the commercial availability of the Ulthera System in select Asian countries to non-invasively treat the skin on the chest area, or décolletage. The Ulthera Sys
- National Eczema Blog Launcheshttps://practicaldermatology.com/news/20120626-national_eczema_blog_launches/2459781/The National Eczema Association recently created a blog featuring guest bloggers on a variety of eczema-related topics. The first post, written by the blogger named “Spanish Key,” provides a patient perspective on eczema research topics and h
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33
- Suneva to Acquire Worldwide Rights to Refissa(R)https://practicaldermatology.com/news/20120604-suneva_to_acquire_worldwide_rights_to_refissar/2459789/Suneva Medical , a privately-held aesthetics company, will acquire worldwide rights to Refissa® and its marketed generic equivalent from Spear Pharmaceuticals. The portfolio contains the only tretinoin creams with
- New School Initiative for Skin Cancer Preventionhttps://practicaldermatology.com/news/20120515-new_school_initiative_for_skin_cancer_prevention/2459798/La Roche-Posay recently collaborated with the Women's Dermatologic Society to launch “Time Out, Protect Your Skin” (TOPS) in schools to educate children and families about skin cancer prevention. New York City's Grace Church School was the first s
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t